BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8282288)

  • 1. [Pharmacokinetics and -dynamics of calcium antagonists in the elderly].
    Spahn-Langguth H; Möhrke W; Mutschler E; Platt D
    Fortschr Med; 1993 Oct; 111(28):441-5. PubMed ID: 8282288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists].
    Rameis H
    Wien Med Wochenschr; 1993; 143(19-20):490-500. PubMed ID: 8135031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium antagonists--determination of current status and therapeutic significance].
    Regenthal R; Voigt H; Preiss R
    Z Gesamte Inn Med; 1992 Dec; 47(12):573-82. PubMed ID: 1283652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pharmacology of calcium inhibitors].
    Singlas E; Martre H; Taburet AM
    Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of calcium entry blockers in elderly patients. Special considerations.
    Wei JY
    Circulation; 1989 Dec; 80(6 Suppl):IV171-7. PubMed ID: 2688981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of age on the pharmacokinetics of nimodipine.
    Mück W; Breuel HP; Kuhlmann J
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):293-8. PubMed ID: 8832305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age.
    Bianchetti G; Billy S; Ascalone V; Saivin S; Houin G; Rosenzweig P
    Int J Clin Pharmacol Ther; 1996 May; 34(5):195-201. PubMed ID: 8738855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amlodipine: pharmacokinetic profile of a low-clearance calcium antagonist.
    Abernethy DR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 1():S4-7. PubMed ID: 16296697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly.
    Felix S; Sproule BA; Hardy BG; Naranjo CA
    J Clin Psychopharmacol; 2003 Oct; 23(5):471-8. PubMed ID: 14520124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-channel antagonists in cardiovascular disease.
    Holdright DR
    Br J Hosp Med; 1997 Jun 4-17; 57(11):552-6. PubMed ID: 9307671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium antagonists. Part 2: Clinical applications].
    Trenkwalder P
    Internist (Berl); 1993 Feb; 34(2):181-4; discussion 185. PubMed ID: 8454434
    [No Abstract]   [Full Text] [Related]  

  • 12. [Calcium antagonists. Part 1: Pharmacology].
    Ziegler A
    Internist (Berl); 1993 Feb; 34(2):178-80. PubMed ID: 8454433
    [No Abstract]   [Full Text] [Related]  

  • 13. [Calcium antagonists. Pharmacology and clinical pharmacology].
    Grobecker H
    Med Monatsschr Pharm; 1994 May; 17(5):130-9. PubMed ID: 8022361
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacodynamics in older adults: a review.
    Bowie MW; Slattum PW
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):263-303. PubMed ID: 17996666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dental changes in patients treated with calcium antagonists].
    Ivanova S; Kiselova-Ianeva A; Dimitrov L; Stanchev N
    Vutr Boles; 1999; 31(4):41-4. PubMed ID: 10989674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of hemodynamic disorders during anesthesia in middle-aged and elderly patients with essential hypertension. Components of anesthesia. II].
    Gur'ianov VA; Gologorskiĭ VA; Martynov AN; Eroshin NI
    Anesteziol Reanimatol; 2000; (5):58-61. PubMed ID: 11220939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiological, pharmacological and pathological factors affecting the pharmacokinetics of calcium entry blockers.
    Padrini R; Piovan D; Bova S; Moretto R; Cargnelli G; Ferrari M
    G Ital Cardiol; 1987 Sep; 17(9):786-90. PubMed ID: 3692080
    [No Abstract]   [Full Text] [Related]  

  • 18. [The pharmacokinetic and pharmacodynamic characteristics of foridon during interaction with the metabolic oxidation inhibitor dopegit].
    Kukes VG; Alekhin SN; Rumiantsev AS; Gneushev ET; Gushchin AS; Germanov DV
    Eksp Klin Farmakol; 1993; 56(5):38-41. PubMed ID: 8312808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Side-effects of calcium inhibitors].
    Lavarenne J
    Therapie; 1989; 44(3):197-200. PubMed ID: 2675381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical assessment of calcium antagonists.
    Krum H
    Aust Fam Physician; 1997 Jul; 26(7):841-5, 847-8. PubMed ID: 9232924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.